TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04289610

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous pulse radiofrequency therapy
Description: Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous pulse radiofrequency therapy
Description: Transcutaneous pulse radiofrequency therapy (TCPRF) is a painless and outpatient physiotherapy modality
Study: NCT02925052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Tube Guide

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional placement
Study: NCT04340284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous adipose tissue derived stromal vascular fraction (SVF)
Description: liquid and solid portion of lipo-aspirate after non enzymatic processing yields SVF.~This isolation process yielded an abundant population of Adipose stromal cells(ASCs) which have multipotent differentiation potential. Immunophenotype is a CD14-, CD29+, CD31-, CD34low/+, CD45-, CD73+ and CD105+ ,~, the SVF represents the 50-70% in volume of a lipoaspirate specimen. The SVF hosts a heterogeneous cell population (110x103 cells/ml on average) comprising mainly CD105+ mesenchymal stem cells (MSC, 20%), plus a wide number of CD34+ hematopoietic cells (40%).
Study: NCT03119636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NPC transplantation
Description: The cells are stereotactically implanted in the striatum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NPC transplantation
Description: The cells are stereotactically implanted in the striatum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NPC transplantation
Description: The cells are stereotactically implanted in the striatum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa is used depending on the patient's condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa is used depending on the patient's condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa is used depending on the patient's condition
Study: NCT02106442

Intervention type: DRUG
Intervention: Sodium risedronate
Description: Sodium risedronate tablets
Study: NCT01570751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
Study: NCT03001999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PP-MI health behavior intervention
Description: The positive psychology exercises include 3 modules:~Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 14 study sessions.
Study: NCT00992212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
Study: NCT03326986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7252
Description: 1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
Study: NCT02498366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical tests
Description: each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3.
Study: NCT01570751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
Study: NCT01091298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)
Description: Single dose (0.5 mL) of the vaccine administered orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (0.5 mL) of the placebo administered orally
Study: NCT00649935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets 600 mg
Description: 600mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax® Tablets 600 mg
Description: 600mg, single dose fed
Study: NCT02217644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 H3PO4 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 H3PO4 low dose capsule
Study: NCT00871533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG- IFNα2b
Description: SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
Study: NCT01874652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Weight Breast Implants
Description: Light Weight Breast Implants
Study: NCT02217644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 H3PO4 high dose capsule
Study: NCT00871533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG- IFNα2b
Description: SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
Study: NCT03285854

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of blood, urine and stool samples
Description: Collection of blood, urine and stool samples, diet diary and bone scans

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of blood, urine and stool samples
Description: Collection of blood, urine and stool samples, diet diary and bone scans
Study: NCT02217644

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03328767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early activity and Mobilisation intervention
Description: The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
Study: NCT02927886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per-oral endoscopy pyloromyotomy
Study: NCT00891618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
Study: NCT02156687

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Y mesh
Description: Y mesh

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual flat mesh
Description: Dual flat mesh
Study: NCT03768856

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Temporally Feathered Radiation Therapy (TFRT)
Description: Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
Study: NCT04637152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.
Study: NCT01971788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography of the infarct related artery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography of the infarct related artery
Study: NCT00588419

Intervention type: BEHAVIORAL
Intervention: breast exam and questionaire
Description: A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
Study: NCT03326986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7252
Description: 1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7252
Description: 1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL
Study: NCT00005086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT01720420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NobelReplace CC, NobelProcera Implant Bar
Description: Implants titanium with conical connection, individualized titanium bar

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NobelReplace CC, NobelProcera Implant Bar
Description: Implants titanium with conical connection, individualized titanium bar
Study: NCT02959476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Inactive comparator
Study: NCT02092883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: PK PET scan before and after ACTH treatment
Study: NCT00588666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT00538655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil
Description: 400mg vs. 200mg (PO) daily
Study: NCT03158831

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo-Controlled Graded Drug Challenge
Description: All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
Study: NCT02107612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Denture
Study: NCT04204941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: 400 mg, 600 to 800 mg of Tazemetostat will be administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCl
Description: 75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: 800 mg administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycle 7 and beyond.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily in continuous 21-day cycles during cycles 1-6 and in continuous 28-day cycles during cycles 7 and beyond

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin HCl
Description: 75mg/m2 intravenous injection day 1 of each cycle for up to 6 cycles
Study: NCT02927886

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intrapyloric injection of Botulinum toxin
Study: NCT00187200

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous VV Pacing
Description: Right ventricular and left ventricular pacing delivered simultaneously.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sequential VV Pacing
Description: Right ventricular and left ventricular pacing delivered sequentially.
Study: NCT00588666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT01337869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bascom Cleft Lift
Description: Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limberg Flap
Description: Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
Study: NCT03829839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intranasal administration, 24 international units (IU) oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam 1 mg
Description: Oral administration of 1mg lorazepam
Study: NCT02819336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Description: The EA group will receive the verum therapies using the following procedures.~1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.~3. The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)~4. After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: 1. Let the patient lie down on lateral decubitus.~2. The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally \& SP11 and SP6 bilaterally.~3. The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.~4. The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.~5. The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days.
Study: NCT03450278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforation
Description: Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
Study: NCT02835768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based injury prevention program
Description: An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum.
Study: NCT02385669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Checkpoint blockade inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6MHP
Description: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
Study: NCT03273348

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oncoplastic breast surgery
Description: , Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
Study: NCT00601848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porfimer sodium

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spectroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT02002819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Study: NCT03570827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Suppression
Description: Given androgen suppression therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Suppression
Description: Given androgen suppression therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01129739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived MSCs
Description: 1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle